Regulatory Update: Saudi Arabia

On February 5, 2024, the Saudi Food & Drug Authority (SFDA) marked a significant milestone with the release of Version 7 of its Guidance for Products Classification. This eagerly anticipated update, approved on November 20, 2023, promises to enhance the classification of various products within the SFDA's jurisdiction, particularly focusing on medical devices and In Vitro Diagnostic (IVD) products.

Key Highlights of Version 7: The latest iteration of the Guidance for Products Classification by the SFDA introduces comprehensive revisions and additional information to streamline the classification process. The aim is to provide clearer guidelines for categorizing a diverse range of products falling under the regulatory purview of the SFDA.

Focus on Medical Devices and IVD Products: One of the notable aspects of Version 7 is its heightened emphasis on the classification of medical devices and IVD Products. These categories play a pivotal role in healthcare, and the SFDA recognizes the need for precise and updated guidelines to ensure the safety and efficacy of such products in the Saudi market.

Implications for the Industry: The release of Version 7 is expected to have far-reaching implications for manufacturers, distributors, and stakeholders in the healthcare industry. Clearer classification criteria will facilitate a more efficient regulatory process, reducing ambiguity and ensuring SFDA standards compliance. 

Collaborative Approach: The SFDA's commitment to providing up-to-date guidance reflects its dedication to fostering a collaborative regulatory environment. The SFDA aims to create a classification system that aligns with global standards and best practices by incorporating feedback from industry experts, manufacturers, and other stakeholders.

You can find the full resource here.